DOCSLIB.ORG

Differences in Recycling of Apolipoprotein E3 and E4—LDL Receptor Complexes—A Mechanistic Hypothesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Differences in Recycling of Apolipoprotein E3 and E4—LDL Receptor Complexes—A Mechanistic Hypothesis International Journal of Molecular Sciences Communication Differences in Recycling of Apolipoprotein E3 and E4—LDL Receptor Complexes—A Mechanistic Hypothesis Meewhi Kim 1,* and Ilya Bezprozvanny 1,2,* 1 Department of Physiology, UT Southwestern Medical Center, Dallas, TX 75390, USA 2 Laboratory of Molecular Neurodegeneration, Peter the Great St. Petersburg State Polytechnic University, 195251 St. Petersburg, Russia * Correspondence: [email protected] (M.K.); [email protected] (I.B.) Abstract: Apolipoprotein E (ApoE) is a protein that plays an important role in the transport of fatty acids and cholesterol and in cellular signaling. On the surface of the cells, ApoE lipoparticles bind to low density lipoprotein receptors (LDLR) that mediate the uptake of the lipids and downstream signaling events. There are three alleles of the human ApoE gene. Presence of ApoE4 allele is a major risk factor for developing Alzheimer’s disease (AD) and other disorders late in life, but the mechanisms responsible for biological differences between different ApoE isoforms are not well understood. We here propose that the differences between ApoE isoforms can be explained by differences in the pH-dependence of the association between ApoE3 and ApoE4 isoforms and LDL-A repeats of LDLR. As a result, the following endocytosis ApoE3-associated LDLRs are recycled back to the plasma membrane but ApoE4-containing LDLR complexes are trapped in late endosomes and targeted for degradation. The proposed mechanism is predicted to lead to a reduction in steady- state surface levels of LDLRs and impaired cellular signaling in ApoE4-expressing cells. We hope that this proposal will stimulate experimental research in this direction that allows the testing of Citation: Kim, M.; Bezprozvanny, I. our hypothesis. Differences in Recycling of Apolipoprotein E3 and E4—LDL Keywords: ApoE; LDL receptor; endosome; Alzheimer’s disease; modelling; protonation; Receptor Complexes—A Mechanistic charged interaction Hypothesis. Int. J. Mol. Sci. 2021, 22, 5030. https://doi.org/10.3390/ ijms22095030 1. Introduction Academic Editor: Michael Ugrumov Apolipoprotein E (ApoE) is a protein that plays an important role in the transport Received: 26 April 2021 of fatty acids and cholesterol and in cellular signaling [1–4]. On the surface of the cells, Accepted: 7 May 2021 ApoE lipoparticles bind to Low Density Lipoprotein receptors (LDLR) that mediate the Published: 10 May 2021 uptake of the lipids and downstream signaling events [1–4]. There are three alleles of the human ApoE gene—E2, E3, and E4—with two of these alleles co-expressed in many tissues, Publisher’s Note: MDPI stays neutral including the central nervous system [4–8]. These alleles differ in amino acids in positions with regard to jurisdictional claims in 112 and 158 of N-terminal ligand domains as follows—E2 (C112, C158), E3(C112, R158) published maps and institutional affil- and E4(R112, R158). There is well established genetic association between the presence of iations. different alleles of the ApoE gene and human diseases [9–13]. In particular, the presence of ApoE4 is a major risk factor for developing Alzheimer’s disease (AD) late in life [14–20]. The mechanisms responsible for biological differences between different ApoE isoforms are not well understood and are currently under intense investigation [21–23]. Copyright: © 2021 by the authors. The ApoE protein is composed of the amino-terminal (N) and carboxy-terminal (C) Licensee MDPI, Basel, Switzerland. domains, which are loosely hinged to each other [24–26]. The N-terminal ligand domain This article is an open access article (LD) is involved in the association with surface receptors including LDLR (Figure1A, distributed under the terms and Supplementary Figure S1); the C-terminal domain is involved in the binding of cholesterol conditions of the Creative Commons and fatty acids [27–29]. Both domains form α-helical bundles [24] with the critical allelic Attribution (CC BY) license (https:// positions C112 and C158, which are located on the side of the fourth and third α-helixes in creativecommons.org/licenses/by/ the ApoE-LD domain. 4.0/). Int. J. Mol. Sci. 2021, 22, 5030. https://doi.org/10.3390/ijms22095030 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2021, 22, x Int. J. Mol. Sci. 2021, 22, 5030 2 of 10 2 of 10 Figure 1. Ligand domain (LD) of ApoE and LDL-A repeats of LDLR. (A) The secondary structure of ApoE-LD and the domainFigure structure 1. Ligand of LDLR domain are shown. (LD) The of receptor-bindingApoE and LDL interface‐A repeats is a partof LDLR. of the fourth(A) Theα-helix secondary in the ApoE-LD structure domain (shownof ApoE in blue).‐LD The and R112C the domain domain portionstructure of theof LDLR third α are-helix shown. in the The ApoE-LD receptor domain‐binding is shown interface in orange. is a part Position 112 withinof the the fourth R112C α‐ domainhelix in is the shown ApoE in purple.‐LD domain Seven amino-terminal(shown in blue). LDL-A The repeatsR112C aredomain shown portion as colored of semicircles.the (B) Primarythird α‐ sequencehelix in alignment the ApoE of‐LD R112C domain domains is shown from ApoE4 in orange. and ApoE3 Position isoforms. 112 Aminowithin acid the inR112C position domain 112 is shownis in redshown (R for ApoE4 in purple. and CSeven for ApoE3). amino (‐Cterminal) Primary LDL sequences‐A repeats of seven are LDL-Ashown repeats as colored from semicircles. the LDLR. The (B sequences) Pri‐ of RP1–RP7mary repeats sequence are color-coded alignment according of R112C to domains the panel Afrom diagram. ApoE4 and ApoE3 isoforms. Amino acid in position 112 is shown in red (R for ApoE4 and C for ApoE3). (C) Primary sequences of seven LDL‐ A repeats from the LDLR.LDLR The sequences is a single transmembraneof RP1–RP7 repeats domain are color protein‐coded that containsaccording seven to the class A repeats panel A diagram. (LDL-A) on its amino terminal (Figure1A, Supplementary Figure S1) [ 30]. These repeats are approximately 40 amino acids long and constrained by three internal disulphide bridges LDLR is a singlethat transmembrane contain conserved domain DCXDXSDE protein motifs that [31 contains] (Supplementary seven class Figure A repeats S1B). These do- (LDL‐A) on its aminomains terminal are involved (Figure in the 1A, association Supplementary with extracellular Figure S1) ligands [30]. [ 2These,6,32]. Therepeats cytosolic tail of LDLR mediates signal transduction and endocytosis [5,33–35]. Similar to other LDLR are approximatelyligands, 40 amino ApoE acids lipoparticles long and bind constrained to LDL-A amino-terminal by three internal repeats disulphide [36–41] (Figure 1A , bridges that containSupplementary conserved Figure DCXDXSDE S1). A ligand motifs binding [31] to (Supplementary the LDLR triggers cellularFigure signalingS1B). trans- These domains areduction involved and in the the internalization association ofwith the extracellular ligand–receptor ligands complex [2,6,32]. via clathrin-assisted The cy‐ en- tosolic tail of LDLRdocytosis mediates [1]. Thesignal internalized transduction complex and is sortedendocytosis to endosomal [5,33–35]. compartments Similar to where the other LDLR ligands,ligand ApoE is released lipoparticles and LDLR bind is recycled to LDL to‐A the amino plasma‐terminal membrane repeats [42–44]. [36–41] Multiple sources (Figure 1A, Supplementaryof evidence Figure demonstrate S1). A that ligand LDLR binding recycling to the requires LDLR organized triggers cellular cellular actions sig‐ includ- ing luminal endosomal acidification and calcium (Ca2+) signaling [45–51]. In particular, naling transduction and the internalization of the ligand–receptor complex via clathrin‐ endosomal acidification plays a key role in the control of LDLR recycling [40,52,53]. assisted endocytosis [1].Interestingly, The internalized experimental complex evidence is sorted suggests to thatendosomal there are compartments significant differences in where the ligand isthe released recycling and of LDLR LDLR complexed is recycled with to ApoE3the plasma or ApoE4 membrane [54–57]. However,[42–44]. Mul a mechanistic‐ tiple sources of evidenceexplanation demonstrate for the differences that LDLR in ApoE3- recycling and ApoE4-containingrequires organized complexes cellular is ac lacking.‐ To tions including luminalexplain endosomal these findings, acidification we propose thatand the calcium observed (Ca differences2+) signaling are due [45–51]. to the In differences particular, endosomalin the acidification pH-dependence plays of the a association key role betweenin the control ApoE3 andof LDLR ApoE4 recycling isoforms and LDL- [40,52,53]. A repeats of the LDLR. As a result, ApoE4-containing but not ApoE3-containing LDLR complexes are trapped in late endosomes and targeted for degradation, leading to a Interestingly,reduction experimental in the evidence steady state suggests surface that levels there of LDLRs are significant and impaired differences cellular signaling in in the recycling of LDLRApoE4-expressing complexed with cells. ApoE3 or ApoE4 [54–57]. However, a mechanistic explanation for the differences in ApoE3‐ and ApoE4‐containing complexes is lacking. To explain these findings, we propose that the observed differences are due to the differences in the pH‐dependence of the association between ApoE3 and ApoE4 isoforms and LDL‐ A repeats of the LDLR. As a result, ApoE4‐containing but not ApoE3‐containing LDLR complexes are trapped in late endosomes and targeted for degradation,
Load more

Recommended publications
  • The VLDL Receptor Regulates Membrane Progesterone Receptor
    © 2018. Published by The Company of Biologists Ltd | Journal of Cell Science (2018) 131, jcs212522. doi:10.1242/jcs.212522 RESEARCH ARTICLE The VLDL receptor regulates membrane progesterone receptor trafficking and non-genomic signaling Nancy Nader, Maya Dib, Raphael Courjaret, Rawad Hodeify, Raya Machaca, Johannes Graumann and Khaled Machaca* ABSTRACT the plasma membrane and interact with the classical P4 receptor, is Progesterone mediates its physiological functions through activation of nonetheless effective at mediating non-genomic P4 signaling both transcription-coupled nuclear receptors and seven-pass- (Bandyopadhyay et al., 1998; Dressing et al., 2011; Peluso et al., transmembrane progesterone receptors (mPRs), which transduce 2002). These results argued for the presence of membrane P4 the rapid non-genomic actions of progesterone by coupling to various receptors that are distinct from the nuclear P4 receptors. In 2003, the signaling modules. However, the immediate mechanisms of action Thomas laboratory identified a family of membrane progesterone downstream of mPRs remain in question. Herein, we use an untargeted receptors (mPRs) from fish ovaries (Zhu et al., 2003a,b) that belong quantitative proteomics approach to identify mPR interactors to better to the progestin and adiponectin (AdipoQ) receptor family (also define progesterone non-genomic signaling. Surprisingly, we identify named PAQ receptors). However, the signal transduction cascade the very-low-density lipoprotein receptor (VLDLR) as an mPRβ downstream of mPRs that mediates the non-genomic actions of P4 (PAQR8) partner that is required for mPRβ plasma membrane remains unclear. localization. Knocking down VLDLR abolishes non-genomic The non-genomic action of mPR and the ensuing signaling progesterone signaling, which is rescued by overexpressing VLDLR.
    [Show full text]
  • LRP2 Is Associated with Plasma Lipid Levels 311 Original Article
    310 Journal of Atherosclerosis and Thrombosis Vol.14, No.6 LRP2 is Associated with Plasma Lipid Levels 311 Original Article Genetic Association of Low-Density Lipoprotein Receptor-Related Protein 2 (LRP2) with Plasma Lipid Levels Akiko Mii1, 2, Toshiaki Nakajima2, Yuko Fujita1, Yasuhiko Iino1, Kouhei Kamimura3, Hideaki Bujo4, Yasushi Saito5, Mitsuru Emi2, and Yasuo Katayama1 1Department of Internal Medicine, Divisions of Neurology, Nephrology, and Rheumatology, Nippon Medical School, Tokyo, Japan. 2Department of Molecular Biology-Institute of Gerontology, Nippon Medical School, Kawasaki, Japan. 3Awa Medical Association Hospital, Chiba, Japan. 4Department of Genome Research and Clinical Application, Graduate School of Medicine, Chiba University, Chiba, Japan. 5Department of Clinical Cell Biology, Graduate School of Medicine, Chiba University, Chiba, Japan. Aim: Not all genetic factors predisposing phenotypic features of dyslipidemia have been identified. We studied the association between the low density lipoprotein-related protein 2 gene (LRP2) and levels of plasma total cholesterol (T-Cho) and LDL-cholesterol (LDL-C) among 352 adults in Japan. Methods: Subjects were obtained from among participants in a cohort study that was carried out with health-check screening in an area of east-central Japan. We selected 352 individuals whose LDL-C levels were higher than 140 mg/dL from the initially screened 22,228 people. We assessed the relation between plasma cholesterol levels and single-nucleotide polymorphisms (SNPs) in the LRP2 gene. Results:
    [Show full text]
  • Apoa5genetic Variants Are Markers for Classic Hyperlipoproteinemia
    CLINICAL RESEARCH CLINICAL RESEARCH www.nature.com/clinicalpractice/cardio APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia 1 1 1 2 2 1 1 Jian Wang , Matthew R Ban , Brooke A Kennedy , Sonia Anand , Salim Yusuf , Murray W Huff , Rebecca L Pollex and Robert A Hegele1* SUMMARY INTRODUCTION Hypertriglyceridemia is a common biochemical Background Several known candidate gene variants are useful markers for diagnosing hyperlipoproteinemia. In an attempt to identify phenotype that is observed in up to 5% of adults. other useful variants, we evaluated the association of two common A plasma triglyceride concentration above APOA5 single-nucleotide polymorphisms across the range of classic 1.7 mmol/l is a defining component of the meta­ 1 hyperlipoproteinemia phenotypes. bolic syndrome and is associated with several comorbidities, including increased risk of cardio­ Methods We assessed plasma lipoprotein profiles and APOA5 S19W and vascular disease2 and pancreatitis.3,4 Factors, –1131T>C genotypes in 678 adults from a single tertiary referral lipid such as an imbalance between caloric intake and clinic and in 373 normolipidemic controls matched for age and sex, all of expenditure, excessive alcohol intake, diabetes, European ancestry. and use of certain medications, are associated Results We observed significant stepwise relationships between APOA5 with hypertriglyceridemia; however, genetic minor allele carrier frequencies and plasma triglyceride quartiles. The factors are also important.5,6 odds ratios for hyperlipoproteinemia types 2B, 3, 4 and 5 in APOA5 S19W Complex traits, such as plasma triglyceride carriers were 3.11 (95% CI 1.63−5.95), 4.76 (2.25−10.1), 2.89 (1.17−7.18) levels, usually do not follow Mendelian patterns of and 6.16 (3.66−10.3), respectively.
    [Show full text]
  • Lrp1 Modulators
    Last updated on February 14, 2021 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Lrp1 Modulators Evidence Summary Lrp1 has a variety of essential functions, mediated by a diverse array of ligands. Therapeutics will need to target specific interactions. Neuroprotective Benefit: Lrp1-mediated interactions promote Aβ clearance, Aβ generation, tau propagation, brain glucose utilization, and brain lipid homeostasis. The therapeutic effect will depend on the interaction targeted. Aging and related health concerns: Lrp1 plays mixed roles in cardiovascular diseases and cancer, dependent on context. Lrp1 is dysregulated in metabolic disease, which may contribute to insulin resistance. Safety: Broad-spectrum Lrp1 modulators are untenable therapeutics due to the high potential for extensive side effects. Therapies that target a specific Lrp1-ligand interaction are expected to have a better therapeutic profile. 1 Last updated on February 14, 2021 Availability: Research use Dose: N/A Chemical formula: N/A S16 is in clinical trials MW: N/A Half life: N/A BBB: Angiopep is a peptide that facilitates BBB penetrance by interacting with Lrp1 Clinical trials: S16, an Lrp1 Observational studies: sLrp1 levels are agonist was tested in healthy altered in Alzheimer’s disease, volunteers (n=10) in a Phase 1 cardiovascular disease, and metabolic study.
    [Show full text]
  • Clusterin and LRP2 Are Critical Components of the Hypothalamic Feeding Regulatory Pathway
    ARTICLE Received 21 Sep 2012 | Accepted 16 Apr 2013 | Published 14 May 2013 DOI: 10.1038/ncomms2896 Clusterin and LRP2 are critical components of the hypothalamic feeding regulatory pathway So Young Gil1, Byung-Soo Youn2, Kyunghee Byun3,4, Hu Huang5, Churl Namkoong1, Pil-Geum Jang1, Joo-Yong Lee1, Young-Hwan Jo6, Gil Myoung Kang1, Hyun-Kyong Kim1, Mi-Seon Shin7, Claus U. Pietrzik8, Bonghee Lee3,4, Young-Bum Kim3,5 & Min-Seon Kim1,7 Hypothalamic feeding circuits are essential for the maintenance of energy balance. There have been intensive efforts to discover new biological molecules involved in these pathways. Here we report that central administration of clusterin, also called apolipoprotein J, causes anorexia, weight loss and activation of hypothalamic signal transduction-activated transcript-3 in mice. In contrast, inhibition of hypothalamic clusterin action results in increased food intake and body weight, leading to adiposity. These effects are likely mediated through the mutual actions of the low-density lipoprotein receptor-related protein-2, a potential receptor for clusterin, and the long-form leptin receptor. In response to clusterin, the low-density lipoprotein receptor-related protein-2 binding to long-form leptin receptor is greatly enhanced in cultured neuronal cells. Furthermore, long-form leptin receptor deficiency or hypothalamic low-density lipoprotein receptor-related protein-2 suppression in mice leads to impaired hypothalamic clusterin signalling and actions. Our study identifies the hypotha- lamic clusterin–low-density lipoprotein receptor-related protein-2 axis as a novel anorexigenic signalling pathway that is tightly coupled with long-form leptin receptor-mediated signalling. 1 Asan Institute for Life Science, University of Ulsan College of Medicine, Seoul 138-736, Korea.
    [Show full text]
  • Apo E Structure Determines VLDL Clearance and Atherosclerosis Risk in Mice
    Apo E structure determines VLDL clearance and atherosclerosis risk in mice Christopher Knouff, … , Patrick M. Sullivan, Nobuyo Maeda J Clin Invest. 1999;103(11):1579-1586. https://doi.org/10.1172/JCI6172. Article We have generated mice expressing the human apo E4 isoform in place of the endogenous murine apo E protein and have compared them with mice expressing the human apo E3 isoform. Plasma lipid and apolipoprotein levels in the mice expressing only the apo E4 isoform (4/4) did not differ significantly from those in mice with the apo E3 isoform (3/3) on chow and were equally elevated in response to increased lipid and cholesterol in their diet. However, on all diets tested, the 4/4 mice had approximately twice the amount of cholesterol, apo E, and apo B-48 in their VLDL as did 3/3 mice. The 4/4 VLDL competed with human LDL for binding to the human LDL receptor slightly better than 3/3 VLDL, but the VLDL clearance rate in 4/4 mice was half that in 3/3 mice. On an atherogenic diet, there was a trend toward greater atherosclerotic plaque size in 4/4 mice compared with 3/3 mice. These data, together with our earlier observations in wild- type and human APOE*2-replacement mice, demonstrate a direct and highly significant correlation between VLDL clearance rate and mean atherosclerotic plaque size. Therefore, differences solely in apo E protein structure are sufficient to cause alterations in VLDL residence time and atherosclerosis risk in mice. Find the latest version: https://jci.me/6172/pdf Apo E structure determines VLDL clearance and atherosclerosis risk in mice Christopher Knouff,1 Myron E.
    [Show full text]
  • UNIVERSITY of CALIFORNIA, SAN DIEGO Intracellular and Extracellular Interactions of the Low Density Lipoprotein Receptor Related
    UNIVERSITY OF CALIFORNIA, SAN DIEGO Intracellular and Extracellular Interactions of the Low Density Lipoprotein Receptor Related Protein (LRP-1) A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Chemistry by Miklos Guttman Committee in charge: Professor Elizabeth Komives, Chair Professor Tracy Handel Professor Kim Prather Professor Susan Taylor Professor Hector Viadiu-Ilarraza 2009 Copyright© Miklos Guttman, 2009 All rights reserved. The dissertation of Miklos Guttman is approved, and it is acceptable in quality and form for publication on microfilmand and electronically: ______________________________________________________ ______________________________________________________ ______________________________________________________ ______________________________________________________ ______________________________________________________ Chair University of California, San Diego 2009 iii TABLE OF CONTENTS Signature Page……………………………………………………................... iii Table of Contents……………………………………………………................ iv List of Symbols and Abbreviations……………………………..................... vi List of Figures…………………………………………………………………… ix List of Tables……………………………………..…………………………….. xi Acknowledgements…………………………….…………………….………… xii Vita, Publications, Fields of Study........……………… …………………….. xiv Abstract of the Dissertation…………………….…………………………….. xvi CHAPTER 1………………………………………………………………... 1 Introduction The LDL family of receptors…….………...….....……………………. 2 The LDL-receptor (LDLR)......…………..……
    [Show full text]
  • Apoer2/VLDL Receptor and Dab1 in the Rostral Migratory Stream Function in Postnatal Neuronal Migration Independently of Reelin
    ApoER2/VLDL receptor and Dab1 in the rostral migratory stream function in postnatal neuronal migration independently of Reelin Nuno Andrade*, Vukoslav Komnenovic†, Sophia M. Blake*, Yves Jossin‡, Brian Howell§, Andre Goffinet‡, Wolfgang J. Schneider*, and Johannes Nimpf*¶ *Max F. Perutz Laboratories, University Departments at the Vienna Biocenter, Department of Medical Biochemistry, Medical University of Vienna, A-1030 Vienna, Austria; †Institute of Molecular Biotechnology, Austrian Academy of Sciences, 1030 Vienna, Austria; ‡Developmental Neurobiology Unit, University of Leuven Medical School, 3000 Leuven, Belgium; and §Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 Edited by Thomas C. Su¨dhof, The University of Texas Southwestern Medical Center, Dallas, TX, and approved March 30, 2007 (received for review December 21, 2006) Postnatal migration of interneuron precursors from the subventricu- In the cerebrum, Reelin is crucial for correct positioning of lar zone to the olfactory bulb occurs in chains that form the substrate radially migrating neuroblasts via its binding to ApoER2 and for the rostral migratory stream. Reelin is suggested to induce de- very-low-density lipoprotein receptor (VLDLR) (18, 19), which tachment of neuroblasts from the chains when they arrive at the triggers tyrosine phosphorylation of the adaptor Dab1 by re- olfactory bulb. Here we show that ApoER2 and possibly very-low- ceptor clustering (20). Binding of Reelin to the receptors and density lipoprotein receptor (VLDLR) and their intracellular adapter subsequent phosphorylation of Dab1 are consecutive steps of a protein Dab1 are involved in chain formation most likely independent linear pathway, because disruption of any of the corresponding of Reelin.
    [Show full text]
  • Dissertation
    DISSERTATION Titel der Dissertation Characterization of Thrombospondin-1 as novel ligand for the Reelin pathway receptors ApoER2 and VLDLR in the postnatal mouse brain angestrebter akademischer Grad Doktor/in der Naturwissenschaften (Dr. rer.nat.) Verfasserin / Verfasser: Sophia Maria Blake Matrikel-Nummer: 0021434 Dissertationsgebiet (lt. Stu- A 091490 Molekulare Biologie dienblatt): Betreuerin / Betreuer: Univ.-Prof. Dr. Johannes Nimpf Wien, am 06. Dezember 2008 Formular Nr.: A.04 Contents 1 Contents 1 Abstract .................................................................................... 3 2 Zusammenfassung .................................................................. 5 3 Introduction .............................................................................. 7 3.1 Neocortical development ..................................................................7 3.1.1 The Neocortex............................................................................. 7 3.1.2 Neuronal migration in the developing neocortex .................... 8 3.1.3 Cortical layering........................................................................ 10 3.1.4 Mouse strains with defects in cortical architecture............... 11 3.1.4.1 reeler................................................................................... 11 3.1.4.2 dab1-/- (scrambler, yotari) .................................................. 11 3.1.4.3 vldlr-/-/apoER2-/- .................................................................. 12 3.2 The Reelin signaling cascade........................................................
    [Show full text]
  • Functional Expression of Low Density Lipoprotein Receptor-Related Protein Is Controlled by Receptor-Associated Protein in Vivo THOMAS E
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 4537-4541, May 1995 Cell Biology Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo THOMAS E. WILLNOW*, SCOTr A. ARMSTRONG*, ROBERT E. HAMMERt, AND JOACHIM HERZ* Departments of *Molecular Genetics and tBiochemistry and Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75235 Communicated by Joseph L. Goldstein, The University of Texas Southwestern Medical Center, Dallas, TX, February 15, 1995 ABSTRACT The 39-kDa receptor-associated protein terminal HNEL tetraamino acid motif has prompted Strick- (RAP) associates with the multifunctional low density li- land et al (32) to propose a possible role of the KDEL receptor poprotein (LDL) receptor-related protein (LRP) and thereby in the process. When RAP is overexpressed the retention prevents the binding of all known ligands, including a2- system becomes saturated and RAP is secreted from the cell, macroglobulin and chylomicron remnants. RAP is predomi- resulting in autocrine/paracrine inhibition of LRP function in nantly localized in the endoplasmic reticulum, raising the vitro and in vivo. We have used this effect in a previous study possibility that it functions as a chaperone or escort protein (33) to provide evidence that LRP participates in the clearance in the biosynthesis or intracellular transport of LRP. Here we of remnant lipoproteins by the liver. have used gene targeting to show that RAP promotes the Based on its biochemical properties RAP has been proposed expression of functional LRP in vivo. The amount of mature, to function as a chaperone during biosynthesis, as an escort processed LRP is reduced in liver and brain of RAP-deficient protein within the secretory pathway, and as a short-acting mice.
    [Show full text]
  • And VLDL Receptor
    International Journal of Molecular Sciences Review The Reelin Receptors Apolipoprotein E receptor 2 (ApoER2) and VLDL Receptor Paula Dlugosz and Johannes Nimpf * Department of Medical Biochemistry, Max F. Perutz Laboratories, Medical University Vienna, 1030 Vienna, Austria; [email protected] * Correspondence: [email protected], Tel.: +43-1-4277-61808, Fax: +43-1-4277-9618 Received: 28 August 2018; Accepted: 3 October 2018; Published: 9 October 2018 Abstract: Apolipoprotein E receptor 2 (ApoER2) and VLDL receptor belong to the low density lipoprotein receptor family and bind apolipoprotein E. These receptors interact with the clathrin machinery to mediate endocytosis of macromolecules but also interact with other adapter proteins to perform as signal transduction receptors. The best characterized signaling pathway in which ApoER2 and VLDL receptor (VLDLR) are involved is the Reelin pathway. This pathway plays a pivotal role in the development of laminated structures of the brain and in synaptic plasticity of the adult brain. Since Reelin and apolipoprotein E, are ligands of ApoER2 and VLDLR, these receptors are of interest with respect to Alzheimer’s disease. We will focus this review on the complex structure of ApoER2 and VLDLR and a recently characterized ligand, namely clusterin. Keywords: apolipoprotein E receptor 2; VLDL receptor; reelin; clusterin; Alzheimer’s disease 1. Introduction Apolipoprotein E receptor 2 (ApoER2) and VLDL receptor (VLDLR) belong to the low density lipoprotein receptor (LDLR) family, a class of type-I transmembrane receptors with high homology to their name-giving member the LDL receptor. Besides more distant members of this family, such as LRP 1, 1b, 2, 5, and 6; ApoER2, VLDLR, and LDLR have a superimposable structure indicating that the corresponding genes may have evolved from one single ancestor by gene duplication events and minor exon rearrangements.
    [Show full text]
  • LRP1 Integrates Murine Macrophage Cholesterol Homeostasis And
    RESEARCH ARTICLE LRP1 integrates murine macrophage cholesterol homeostasis and inflammatory responses in atherosclerosis Xunde Xian1†*, Yinyuan Ding1,2†, Marco Dieckmann1†, Li Zhou1, Florian Plattner3,4, Mingxia Liu5, John S Parks5, Robert E Hammer6, Philippe Boucher7, Shirling Tsai8,9, Joachim Herz1,4,10,11* 1Departments of Molecular Genetics, UT Southwestern Medical Center, Dallas, United States; 2Key Laboratory of Medical Electrophysiology, Ministry of Education of China, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China; 3Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, United States; 4Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, United States; 5Section on Molecular Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina; 6Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, United States; 7CNRS, UMR 7213, University of Strasbourg, Illkirch, France; 8Department of Surgery, UT Southwestern Medical Center, Dallas, United States; 9Dallas VA Medical Center, Dallas, United States; 10Department of Neuroscience, UT Southwestern, Dallas, United States; 11Department of Neurology and Neurotherapeutics, UT Southwestern, Dallas, United States *For correspondence: [email protected] (XX); [email protected] Abstract Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional cell (JH) surface
    [Show full text]